- Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the company's 13 director nominees were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the 2025 fiscal year. In addition, shareholders supported the board-sponsored proposal to approve the compensation of the company's named executive officers, on an advisory basis.
In other voting, shareholders did not support the two shareholder-sponsored proposals.
"We thank all shareholders for their participation today and for their ongoing support. 2024 was a year of focus and execution in which we delivered on our financial commitments, strengthened the company, and importantly, made a positive impact for patients. I'm confident that the underlying foundation of our company is strong and that we are well positioned to create sustained, long-term value for shareholders," stated Albert Bourla, Pfizer Chairman and Chief Executive Officer.
The final results are subject to verification by the independent inspectors of election. The final results will be reported on a Current Report on Form 8-K to be filed by Pfizer with the U.S. Securities and Exchange Commission in the next few days.
